


FIGURE 1



The image displays two protein structures, Kunitz-1 and Kunitz-2, represented as circular diagrams with amino acid residues in circles connected by lines. Kunitz-1 is a single chain, and Kunitz-2 is a dimeric structure with two chains.

Kunitz-1 (top diagram) shows a single chain with the following amino acid sequence (starting from the top and moving clockwise):

- Y, R, D, C, K, R, A, C, X, A, L, K, K, X, X, X, M, P, K, L, R, E, A, R, T, R, K, H, K, K, Q, F

Kunitz-2 (bottom diagram) shows a dimeric structure with two chains. The left chain (starting from the top and moving clockwise) has the sequence:

- Y, R, D, C, K, R, A, C, X, A, L, K, K, X, X, X, M, P, K, L, R, E, A, R, T, R, K, H, K, K, Q, F

The right chain (starting from the top and moving clockwise) has the sequence:

- Y, R, D, C, K, R, A, C, X, A, L, K, K, X, X, X, M, P, K, L, R, E, A, R, T, R, K, H, K, K, Q, F

FIGURE 3




FIGURE 4




FIGURE 5

TFPI Peptide Inhibition of HUVEC Proliferation
bFGF vs VEGF




FIGURE 6

TFPI Peptide Inhibition of Tumor Cells




FIGURE 7

Inhibition of RAP Binding to Immobilized sVLDLr1-8
JFR-24 August 2001




FIGURE 8

TFPI Peptide Inhibition of Huvec
Effect of VLDLr Antibody




FIGURE 9

Inhibition of LLC Metastases by TFPI Peptide




FIGURE 10

SEQ ID NO: 1

Lys	Gln	Glu	Cys	Leu	Arg	Ala	Cys	Lys	Lys		
Gly	Phe	Ile	Gln	Arg	Ile	Ser	Lys	Gly	Gly	Lev	Ile
Lys	Thr	Lys	Arg	Lys	Arg	Lys	Lys	Gln	Arg	Val	Lys
Ile	Ala	Tyr	Glu	Glu	Ile	Phe	Val	Lys	Asn	Met	

SEQ ID NO: 2

Ile	Ser	Lys	Gly	Gly	Leu	Ile					
Lys	Thr	Lys	Arg	Lys	Arg	Lys	Lys	Gln	Arg	Val	Lys
Ile	Ala	Tyr	Glu	Glu	Ile	Phe	Val	Lys	Asn	Met	

SEQ ID NO: 3

Lys	Thr	Lys	Arg	Lys	Arg	Lys	Lys	Gln	Arg	Val	Lys
Ile	Ala	Tyr	Glu	Glu	Ile	Phe	Val	Lys	Asn	Met	

SEQ ID NO: 4

Lys	Lys	Lys	Lys	Lys	Met	Phe	Lys	Leu	Arg	Phe	Ala
Ser	Arg	Ile	Arg	Lys	Ile	Arg	Lys	Lys	Gln	Phe	

Downloaded from www.sciencedirect.com

FIGURE 11

Asp	Ser	Glu	Glu	Asp	Glu	Glu	His	Thr	Ile	Ile	Thr	Asp	Thr	Glu	Leu	1	5	10	15
Pro	Pro	Leu	Lys	Leu	Met	His	Ser	Phe	Cys	Ala	Phe	Lys	Ala	Asp	Asp	20	25	30	
Gly	Pro	Cys	Lys	Ala	Ile	Met	Lys	Arg	Phe	Phe	Phe	Asn	Ile	Phe	Thr	35	40	45	
Arg	Gln	Cys	Glu	Glu	Phe	Ile	Tyr	Gly	Gly	Cys	Glu	Gly	Asn	Gln	Asn	50	55	60	
Arg	Phe	Glu	Ser	Leu	Glu	Glu	Cys	Lys	Lys	Met	Cys	Thr	Arg	Asp	Asn	65	70	75	80
Ala	Asn	Arg	Ile	Ile	Lys	Thr	Thr	Leu	Gln	Gln	Glu	Lys	Pro	Asp	Phe	85	90	95	
Cys	Phe	Leu	Glu	Glu	Asp	Pro	Gly	Ile	Cys	Arg	Gly	Tyr	Ile	Thr	Arg	100	105	110	
Tyr	Phe	Tyr	Asn	Asn	Gln	Thr	Lys	Gln	Cys	Glu	Arg	Phe	Lys	Tyr	Gly	115	120	125	
Gly	Cys	Leu	Gly	Asn	Met	Asn	Asn	Phe	Glu	Thr	Leu	Glu	Glu	Cys	Lys	130	135	140	
Asn	Ile	Cys	Glu	Asp	Gly	Pro	Asn	Gly	Phe	Gln	Val	Asp	Asn	Tyr	Gly	145	150	155	160
Thr	Gln	Leu	Asn	Ala	Val	Asn	Asn	Ser	Leu	Thr	Pro	Gln	Ser	Thr	Lys	165	170	175	
Val	Pro	Ser	Leu	Phe	Glu	Phe	His	Gly	Pro	Ser	Trp	Cys	Leu	Thr	Pro	180	185	190	
Ala	Asp	Arg	Gly	Leu	Cys	Arg	Ala	Asn	Glu	Asn	Arg	Phe	Tyr	Tyr	Asn	195	200	205	
Ser	Val	Ile	Gly	Lys	Cys	Arg	Pro	Phe	Lys	Tyr	Ser	Gly	Cys	Gly	Gly	210	215	220	
Asn	Glu	Asn	Asn	Phe	Thr	Ser	Lys	Gln	Glu	Cys	Leu	Arg	Ala	Cys	Lys	225	230	235	240
Lys	Gly	Phe	Ile	Gln	Arg	Ile	Ser	Lys	Gly	Gly	Leu	Ile	Lys	Thr	Lys	245	250	255	
Arg	Lys	Arg	Lys	Lys	Gln	Arg	Val	Lys	Ile	Ala	Tyr	Glu	Glu	Ile	Phe	260	265	270	
Val	Lys	Asn	Met													275			

20220919 9:49:00

FIGURE 12


Asp	Ala	Ala	Gln	Glu	Pro	Thr	Gly	Asn	Asn	Ala	Glu	Ile	Cys	Leu	Leu	
1				5					10					15		
Pro	Leu	Asp	Tyr	Gly	Pro	Cys	Arg	Ala	Leu	Leu	Leu	Arg	Tyr	Tyr	Tyr	
			20					25					30			
Asp	Arg	Tyr	Thr	Gln	Ser	Cys	Arg	Gln	Phe	Leu	Tyr	Gly	Gly	Cys	Glu	
		35					40					45				
Gly	Asn	Ala	Asn	Asn	Phe	Tyr	Thr	Trp	Glu	Ala	Cys	Asp	Asp	Ala	Cys	
	50					55					60					
Trp	Arg	Ile	Glu	Lys	Val	Pro	Lys	Val	Cys	Arg	Leu	Gln	Val	Ser	Val	
65					70					75					80	
Asp	Asp	Gln	Cys	Glu	Gly	Ser	Thr	Glu	Lys	Tyr	Phe	Phe	Asn	Leu	Ser	
				85					90					95		
Ser	Met	Thr	Cys	Glu	Lys	Phe	Phe	Ser	Gly	Gly	Cys	His	Arg	Asn	Arg	
			100					105					110			
Ile	Glu	Asn	Arg	Phe	Pro	Asp	Glu	Ala	Thr	Cys	Met	Gly	Phe	Cys	Ala	
		115					120					125				
Pro	Lys	Lys	Ile	Pro	Ser	Phe	Cys	Tyr	Ser	Pro	Lys	Asp	Glu	Gly	Leu	
	130					135					140					
145																
Cys	Ser	Ala	Asn	Val	Thr	Arg	Tyr	Tyr	Phe	Asn	Pro	Arg	Tyr	Arg	Thr	
145					150					155					160	
Cys	Asp	Ala	Phe	Thr	Tyr	Thr	Gly	Cys	Gly	Gly	Asn	Asp	Asn	Asn	Phe	
				165					170					175		
Val	Ser	Arg	Glu	Asp	Cys	Lys	Arg	Ala	Cys	Ala	Lys	Ala	Leu	Lys	Lys	
			180					185					190			
Lys	Lys	Lys	Met	Pro	Lys	Leu	Arg	Phe	Ala	Ser	Arg	Ile	Arg	Lys	Ile	
		195					200					205				
Arg	Lys	Lys	Gln	Phe												
			210													

202201 9/15/2001

Figure 13 (a-c)


5 μ M TFPI

C-Terminal Peptide




20 μ M TFPI

C-Terminal Peptide



50 μ M TFPI

C-Terminal Peptide




208220 9/19/00
Figure 14 (a-d)


20 μ M TFPI
C-Terminal Peptide




20 μ M TFPI
C-Terminal Peptide
+ Ab



Control + Ab



Control



2008220 "9/198001
Figure 15

TFPI Peptide + VLDL Antibody

